Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | PTPRA | P18433 | 1/20 | 0.57 |
| ▸ | PTPRB | P23467 | 1/20 | 0.57 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4954416 | 1.00 | CYP1A2 (0.57) | CYP1A2CYP2C9HIF1ATSHRCYP2C19 | |
| SCHEMBL4954382 | 1.00 | CYP1A2 (0.57) | CYP1A2CYP2C9HIF1ATSHRCYP2C19 | |
| SCHEMBL29868768 | 1.00 | CYP1A2 (0.57) | CYP1A2CYP2C9HIF1ATSHRCYP2C19 | |
| SCHEMBL17088271 | 0.88 | CYP1A2 (0.52) | CYP1A2CYP2C9HIF1ATSHRCYP2C19 | |
| SCHEMBL12954983 | 0.87 | CYP1A2 (0.58) | CYP1A2CYP2C9HIF1ATSHRCYP2C19 | |
| SCHEMBL17089143 | 0.86 | CD40 (0.50) | CYP1A2CYP2C9HIF1ATSHRCYP2C19 | |
| SCHEMBL24026725 | 0.83 | HPGD (0.51) | CYP1A2CYP2C9HIF1ATSHRCYP2C19 | |
| SCHEMBL10896861 | 0.83 | CYP1A2 (0.62) | CYP1A2CYP2C9HIF1ATSHRCYP2C19 | |
| SCHEMBL11759913 | 0.83 | CYP1A2 (0.62) | CYP1A2CYP2C9HIF1ATSHRCYP2C19 | |
| SCHEMBL11672613 | 0.83 | CYP1A2 (0.50) | CYP1A2CYP2C9HIF1ATSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240167107-A1 | COMPOSITION AND METHOD FOR NUCLEIC ACID DETECTION | APTITUDE MEDICAL SYSTEMS, INC. (US) | 2024-05-23 | — | — | US | claimed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | claimed |
| WO-2005083081-A1 | IMPROVED NUCLEASE INHIBITOR COCKTAIL | AMBION, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| US-20050014169-A1 | Nuclease inhibitor cocktail | AMBION, INC. | 2005-01-20 | — | — | US | claimed |
| US-20240167107-A1 | COMPOSITION AND METHOD FOR NUCLEIC ACID DETECTION | APTITUDE MEDICAL SYSTEMS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| WO-2008157747-A1 | USE OF INHIBITION OF EXONUCLEASE 1 IN METHODS FOR THERAPY AND DIAGNOSTIC OF NEURODEGENERATIVE DISEASES, EYE DISEASES, AND MITOCHONDRIAL DISORDERS | THE JACKSON LABORATORY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | AMBION, INC (US) | 2007-02-08 | — | — | US | disclosed |
| WO-2005083081-A1 | IMPROVED NUCLEASE INHIBITOR COCKTAIL | AMBION, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050014169-A1 | Nuclease inhibitor cocktail | AMBION, INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | RNASE1, RNASEH1, RNASEL | CYP1A2 4375/4885CYP2C9 4801/4885HIF1A 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.